TABLE 1
FROM:
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias
J M Burke, P C Caron, E B Papadopoulos, C R Divgi, G Sgouros, K S Panageas, R D Finn, S M Larson, R J O'Reilly, D A Scheinberg and J G Jurcic
BACK TO ARTICLETable 1. Patient characteristics
| No. of patients | 32 |
| Median age (years) (range) | 38 (4–60) |
| Number male/female | 22/10 |
Median marrow cell doses ( 108/kg) (range) | 2.55 (0.15–8.3) |
| Diagnosis | |
| AML | 17 |
| de novo, primary refractory | 6 |
| First relapse | 5 |
| Second relapse | 1 |
| Secondary, refractory | 4 |
| Relapse after BMT | 1 |
| CML | 14 |
| Accelerated phase | 5 |
| Blastic phase | 6 |
| Relapse after BMT | 3 |
| RAEB | 1 |
| GVHD prophylaxis | |
| CSA+MP | 23 |
| CSA+MTX | 7 |
| CSA+MP+MTX | 1 |
| CSA+MTX+ATG | 1 |
AML=acute myeloid leukemia; CML=chronic myeloid leukemia; RAEB=refractory anemia with excess blasts; CSA=cyclosporin A; MP=methylprednisolone; MTX=methotrexate; ATG=antithymocyte globulin.
